US Stock MarketDetailed Quotes

ALC Alcon

Watchlist
  • 94.930
  • -0.840-0.88%
Close Mar 31 16:00 ET
  • 94.930
  • 0.0000.00%
Post 16:45 ET
46.95BMarket Cap46.31P/E (TTM)

About Alcon Company

Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the Surgical and Vision Care segments. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner in 1945 and is headquartered in Geneva, Switzerland.

Company Profile

SymbolALC
Company NameAlcon
Listing DateApr 9, 2019
Founded1945
CEOMr. David J. Endicott
MarketNYSE
Employees25000
Fiscal Year Ends12-31
AddressRoyce Bedward,Chemin de Blandonnet 8,Vernier
CityGeneva
ProvinceGeneve (Geneva)
CountrySwitzerland
Zip Code1214
Phone41-817-293-04-50

Company Executives

  • Name
  • Position
  • Salary
  • David J. Endicott
  • Director and Chief Executive Officer
  • 13.24M
  • Kimberly Martin
  • Senior Vice President and Chief Human Resources and Corporate Communication Officer
  • --
  • Timothy C. Stonesifer
  • Senior Vice President and Chief Financial Officer
  • --
  • Ian Bell
  • Senior Vice President and Chief Operating Officer
  • --
  • Rajkumar Narayanan
  • Senior Vice President and President, International
  • --
  • Leon Sergio Duplan Fraustro
  • Senior Vice President and President, Americas
  • --
  • Laurent Attias
  • Senior Vice President, Corporate Strategy, Business Development and Licensing and Mergers and Acquisitions
  • --
  • F. Michael Ball
  • Chairman of the Board
  • 1.47M
  • D. Keith Grossman
  • Vice Chairman of the Board
  • 382.38K
  • Lynn Dorsey Bleil
  • Independent Director
  • 308.47K
  • Karen J. May
  • Independent Director
  • 342.63K
  • Ines Poschel
  • Independent Director
  • 307.48K
  • Thomas H. Glanzmann
  • Independent Director
  • 376.55K
  • Scott H. Maw
  • Independent Director
  • 391.81K
  • Dieter Spalti, PhD
  • Independent Director
  • 280.01K
  • Dr. Raquel C. Bono, M.D.
  • Independent Director
  • 276.85K
  • Dr. Arthur Cummings, M.D.
  • Independent Director
  • 300.14K

Market Insights

Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Unlock Now
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina Show More